New anti-lung cancer drug CM118 will enter clinical
-
Last Update: 2020-06-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Business Association March 6, Shanghai Re-New Pharmaceutical Technology Co., Ltdannounced that the company's new anti-lung cancer drug CM118 project has completed preclinical research, and submitted clinical applications to the Shanghai Food and Drug AdministrationCM118 is a selective MET kinase and ALK kinase inhibitor, it is directly aimed at pfizer has been listed in the United States new ALK kinase inhibitor anti-lung cancer new drug cantini designed to retain its advantages on the basis of further overcoming the shortcomings of the drug interaction of keretinib, expand the possibility of this new type of anticancer drugs and other anti-cancer drugs combined with the application, greatly improve the therapeutic effectpreclinical trial results show that CM118 is likely to meet the desired design objectivesAt the same time, MET kinase is directly related to the growth and metastasis oftumor
stoicism, and it is also an important drug resistance mechanism of high-end anti-cancer drugs such as Elotinani, Gifitinib and Avastin, which are commonly used in the clinicClinical trials of MET kinase inhibitors have shown that they have good effects on non-small cell lung cancer
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
